On August 21, 2018, it was announced that at the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the mechanism of action and the immunomodulatory capacities of CAP-2003, the company’s investigational therapy comprised of proprietary extracellular vesicles (EVs), including exosomes, which are derived from cardiosphere-derived cells (CDC-EVs). Capricor is developing CAP-2003 as a therapeutic platform for treating diseases involving inflammation and fibrosis. The Gordon Research Conference on Extracellular Vesicles is focused on cutting-edge research on the biogenesis, molecular composition, functions, physio-pathological roles, and potential clinical applications of extracellular vesicles. Gordon Research Conferences are a group of prestigious international scientific conferences that are at the forefront of research in the biological, chemical, and physical sciences, and their related technologies. “The pre-clinical studies presented at the Gordon Research Conference further elucidate Capricor’s progress in developing this exciting new class of therapeutics, the exosomes which comprise our investigational therapy, CAP-2003,” said Linda Marbán, PhD, Capricor CEO. “The studies further demonstrate that exosomes may be the active pharmaceutical ingredient (API) in CAP-1002, our cell therapy product, because these extracellular vesicles serve as cellular-messengers, altering function and physiology to balance inflammation so that cellular repair can be facilitated.” In the first study, Capricor compared CAP-2003 with exosomes made from mesenchymal stem cells (MSCs).
Login Or Register To Read Full Story